Gene · 147
ADRA1B: adrenoceptor alpha 1B
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. ADRA1B: adrenoceptor alpha 1B. Genes, record 147. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/147
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| P35368 | Alpha-1B adrenergic receptor | 520 | 0 | Ensembl, GeneID, HGNC |
Source UniProt
Patents38
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026062654 A | 2026-04-10 | 19 | P35368 | Espacenet |
| JP 2026004568 A | 2026-01-14 | 36844 | P35368 | Espacenet |
| JP 2025529142 A | 2025-09-04 | 332 | P35368 | Espacenet |
| US 12371689 B2 | 2025-07-29 | 332 | P35368 | Espacenet |
| JP 2025062604 A | 2025-04-14 | 3465 | P35368 | Espacenet |
| JP 2025032204 A | 2025-03-11 | 24240 | P35368 | Espacenet |
| EP 4461818 A2 | 2024-11-13 | 24240 | P35368 | Espacenet |
| JP 2023156353 A | 2023-10-24 | 19 | P35368 | Espacenet |
| JP 2023058610 A | 2023-04-25 | 24240 | P35368 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 3465 | P35368 | Espacenet |
1 to 10 of 38
See all 38 patentsDrugs67
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ALFUZOSIN | CHEMBL709 | Adrenergic receptor alpha-1 agonist | AGONIST | ChEMBL |
| ALFUZOSIN HYDROCHLORIDE | CHEMBL1723 | Adrenergic receptor alpha-1 agonist | AGONIST | ChEMBL |
| ALSEROXYLON | CHEMBL1201454 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| AVIPTADIL | CHEMBL1981592 | Adrenergic receptor alpha antagonist | ANTAGONIST | ChEMBL |
| BUCINDOLOL | CHEMBL321582 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| BUCINDOLOL HYDROCHLORIDE | CHEMBL2107546 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| BUNAZOSIN | CHEMBL188185 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| CARVEDILOL | CHEMBL723 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| CARVEDILOL PHOSPHATE | CHEMBL1201167 | Adrenergic receptor alpha-1 antagonist | ANTAGONIST | ChEMBL |
| DIPIVEFRIN | CHEMBL1201262 | Adrenergic receptor agonist | AGONIST | ChEMBL |
1 to 10 of 67
See all 67 drugsTrials751
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07577518 | CARVEDILOL | ClinicalTrials.gov | ||
| NCT07572656 | LABETALOL | ClinicalTrials.gov | ||
| NCT07464028 | TERAZOSIN | PHASE2 | ClinicalTrials.gov | |
| NCT07442643 | EPINEPHRINE | ClinicalTrials.gov | ||
| NCT07442071 | EPINEPHRINE | PHASE3 | ClinicalTrials.gov | |
| NCT07432997 | MIDODRINE | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07422948 | MIDODRINE | ClinicalTrials.gov | ||
| NCT07398508 | DROXIDOPA | PHASE1/PHASE2 | ClinicalTrials.gov | |
| NCT07364201 | LABETALOL | ClinicalTrials.gov | ||
| NCT07363343 | LABETALOL | ClinicalTrials.gov |
1 to 10 of 751
See all 751 trialsNIH grants1,008
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | ADRA1B papers | Newest fiscal year |
|---|---|---|---|
| R01HL016037 | Molecular Regulation of Cardiovascular 7 TM Receptors | 10 | 2025 |
| R01MH084894 | Function of GPCR heteromeric complexes in brain | 3 | 2025 |
| I01BX000740 | Right Heart Function in Health and Chronic Disease | 2 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 2 | 2025 |
| P30ES017885 | Michigan Center on Lifestage Environmental Exposures and Disease (M-LEEaD) | 2 | 2025 |
| P51OD011132 | Emory National Primate Research Center | 2 | 2025 |
| R35GM152056 | Regulation of vascular function after traumatic-hemorrhagic shock and during inflammation | 2 | 2025 |
| T32GM007569 | Clinical Pharmacology Training Program | 2 | 2025 |
| U19AI077439 | Immune-driven Airway Epithelial Dysfunction in Muco-obstructive Asthma | 2 | 2025 |
| ZIADK031116 | Development of P2Y Receptor Ligands | 2 | 2025 |
1 to 10 of 1,008Source NIH's project files
See all 1,008 nih grantsPapers1,256
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Local sympathetic signal enables the immune evasion of hepatic stellate cells. | Neuron | 2026 | 42748918 | PubTator, text mining | PubMed |
| α 1A-Adrenergic receptor (ADRA1A) signaling signatures as prognostic biomarkers in liver hepatocellular carcinoma: a bioinformatic analysis. | In Silico Pharmacol | 2026 | 42542688 | PubTator, text mining | PubMed |
| Neuroticism is linked to cognitive decline and increased risk of Alzheimer's disease through dysregulation of excitatory neurons. | bioRxiv | 2026 | 42427719 | PubTator, text mining | PubMed |
| Potential Cardiovascular Risks of Phenethylamine Analogues in Food Supplements: Evidence from Vasocontraction of Rat Artery Segments. | Cardiovasc Toxicol | 2026 | 41934574 | PubTator, text mining | PubMed |
| Molecular Boolean analyses of chemokine (C-C motif) receptor 1, α1B-adrenoceptor and arginine vasopressin receptor 1A heteromers. | Biochem Biophys Rep | 2026 | 41867271 | PubTator, text mining | PubMed |
| Synergistic Effect of Combination Treatment of Brexpiprazole and Nalmefene on Ethanol Intake in Rats. | Neuropsychopharmacol Rep | 2026 | 41793049 | PubTator, text mining | PubMed |
| Health risk analysis of micro-and nanoplastic exposure via the microbiota-gut-brain axis. | Front Immunol | 2026 | 41789083 | PubTator, text mining | PubMed |
| Exploring the Impact of E‑Waste Exposure on Childhood Blood Pressure: Metabolomics Analysis and Risk Prediction. | Environ Health (Wash) | 2026 | 41743803 | PubTator, text mining | PubMed |
| The Intersection of m6A Methylation and Immune Response in PCOS: A Bioinformatics Perspective. | Immun Inflamm Dis | 2026 | 41725222 | PubTator, text mining | PubMed |
| Somatic Mutations Profiling in Genes Other than BRCA and TP53 Increasing Breast Carcinoma Risk Among Pakistani Patients. | Rev Recent Clin Trials | 2026 | 40755100 | PubTator, text mining | PubMed |
1 to 10 of 1,256
See all 1,256 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/147
GET https://conductscience.org/api/genes/v1/147/patents?page=2